2-amino-N-(4-trifluoromethoxyphenyl)benzamide | 263559-01-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-N-(4-trifluoromethoxyphenyl)benzamide
• 英文别名: 2-amino-N-[4-(trifluoromethoxy)phenyl]benzamide
• CAS: 263559-01-9
• 化学式: C₁₄H₁₁F₃N₂O₂
• 分子量: 296.249
• InChiKey: LEXCDQLJUIFYHC-UHFFFAOYSA-N

物化性质

• 沸点：
  318.1±42.0 °C(Predicted)
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  甲基硼酸 、 2-amino-N-(4-trifluoromethoxyphenyl)benzamide 在 无水氯化铜 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 12.0h， 生成
  参考文献：
  名称：

  Electrochemical utilization of methanol and methanol-d4 as a C1 source to access (deuterated) 2,3-dihydroquinazolin-4(1H)-one

  摘要：

  DOI：

  10.1016/j.cclet.2021.09.019
• 作为产物：
  描述：

  对三氟甲氧基苯胺 在 10 percent Pd/C 吡啶 、 氢气 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-amino-N-(4-trifluoromethoxyphenyl)benzamide
  参考文献：
  名称：

  N²-Aroylanthranilamide Inhibitors of Human Factor Xa

  摘要：

  Reversal of the A-ring amide link in 1,2-dibenzamidobenzene 1 (fXa K-ass = 0.81 x 10(6) L/mol) led to a series of human factor Xa (hfXa) inhibitors based on N-2-aroylanthranilamide 4. Expansion of the SAR around 4 showed that only small planar substituents could be accommodated in the A-ring for binding to the S1 site of hfXa. Bulky groups such as 4-isopropyl, 4-tert-butyl, and C-dimethylamino were favored in the B-ring to interact with the S4 site of hfXa. The central (C) ring containing a 5-methanesulfonamido group yielded greater activity than carbamoyl groups. Combining the beneficial features from the B- and C-ring SAR, compound 55 represents the most potent hfXa inhibitor in the N-2-aroylanthranilamide 4 series with hfXa K-ass = 58 x 10(6) L/mol (K-i = 11.5 nM).

  DOI：

  10.1021/jm990327e

文献信息

• Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system
  作者：Tsukasa Ishihara、Yuji Koga、Yoshiyuki Iwatsuki、Fukushi Hirayama

  DOI：10.1016/j.bmc.2014.11.042

  日期：2015.1

  installation of phenolic hydroxyl group and extensive exploration of the P1 binding element led to the identification of 5-chloro-N-(5-chloro-2-pyridyl)-3-hydroxy-2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzamide (33, AS1468240) as a potent factor Xa inhibitor with significant oral anticoagulant activity. We also reported a newly developed Free-Wilson-like fragment recommender system based on the integration

  抗凝剂已经成为用于治疗和预防动脉和静脉血栓形成的有前途的一类治疗药物。我们研究了一系列新颖的口服活性因子Xa抑制剂，这些抑制剂使用我们先前报道的结合策略设计，以增强口服抗凝作用。邻苯二甲酰胺衍生物3作为先导化合物的结构优化与酚羟基的安装以及对P1结合元素的广泛探索导致对5-氯-N-（5-氯-2-吡啶基）-3-羟基-2的鉴定-[[4-（4-甲基-1,4-二氮杂-1-基）苯甲酰基]氨基}苯甲酰胺（33（AS1468240）作为有效的Xa抑制剂，具有显着的口服抗凝活性。我们还报告了一个新开发的类似Free-Wilson的片段推荐系统，该系统基于R-group分解与协作过滤的集成，用于结构优化过程。
• COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
  申请人：Hansen Henrik C.

  公开号：US20110294807A1

  公开（公告）日：2011-12-01

  Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds. Formula (I)

  本发明揭示了一种新型化合物，可用于调节载脂蛋白A-I（ApoA-I）的表达，并且其用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关疾病，例如动脉粥样硬化。还揭示了包含这种新型化合物的药物组合物。公式（I）
• Compounds for the prevention and treatment of cardiovascular disease
  申请人：RESVERLOGIX CORP.

  公开号：EP2660238A1

  公开（公告）日：2013-11-06

  Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds.

  所公开的新型化合物可用于调节载脂蛋白 A-I（ApoA-I）的表达，并可用于治疗和预防心血管疾病及相关疾病状态，包括胆固醇或脂质相关疾病，如动脉粥样硬化等。还公开了包含这些新型化合物的药物组合物。
• US8952021B2
  申请人：——

  公开号：US8952021B2

  公开（公告）日：2015-02-10
• <i>N</i>²-Aroylanthranilamide Inhibitors of Human Factor Xa
  作者：Ying K. Yee、Anne Louise Tebbe、Jared H. Linebarger、Douglas W. Beight、Trelia J. Craft、Donetta Gifford-Moore、Theodore Goodson、David K. Herron、Valentine J. Klimkowski、Jeffrey A. Kyle、J. Scott Sawyer、Gerald F. Smith、Jennifer M. Tinsley、Richard D. Towner、Leonard Weir、Michael R. Wiley

  DOI：10.1021/jm990327e

  日期：2000.3.1

  Reversal of the A-ring amide link in 1,2-dibenzamidobenzene 1 (fXa K-ass = 0.81 x 10(6) L/mol) led to a series of human factor Xa (hfXa) inhibitors based on N-2-aroylanthranilamide 4. Expansion of the SAR around 4 showed that only small planar substituents could be accommodated in the A-ring for binding to the S1 site of hfXa. Bulky groups such as 4-isopropyl, 4-tert-butyl, and C-dimethylamino were favored in the B-ring to interact with the S4 site of hfXa. The central (C) ring containing a 5-methanesulfonamido group yielded greater activity than carbamoyl groups. Combining the beneficial features from the B- and C-ring SAR, compound 55 represents the most potent hfXa inhibitor in the N-2-aroylanthranilamide 4 series with hfXa K-ass = 58 x 10(6) L/mol (K-i = 11.5 nM).